Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.
Aug 2026· Hepatology International· 1 citation· 23 references
Medicine
TL;DR
The role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification is supported, and impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors is independently associated with impaired kidney function in patients with MASLD.
Abstract
Background
AND
Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic metabolic disorder associated with extrahepatic organ damage, including chronic kidney disease (CKD). The Fibrosis-4 (FIB-4) index is a validated non-invasive tool for estimating hepatic fibrosis severity. This study aimed to investigate whether FIB-4-defined hepatic fibrosis is independently associated with reduced estimated glomerular filtration rate (eGFR) in a large, real-world Turkish MASLD cohort.
Methods
This is a cross-sectional analysis of the prospective, nationwide, multicenter DAHUDER MASLD Study, which enrolled patients from 44 internal medicine outpatient clinics across 31 provinces representing all 12 statistical regions of Türkiye. A total of 10,873 MASLD patients were included. MASLD was defined as ultrasonographic hepatic steatosis in the presence of at least one cardiometabolic risk factor. High FIB-4 was defined as ≥ 1.3 for patients aged < 65 years and ≥ 2.0 for those aged ≥ 65 years, per EASL-EASD-EASO 2024 guidelines. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Age-stratified multivariate linear regression models were constructed to identify independent predictors of eGFR.
Results
High FIB-4 was detected in 11.2% of the patients (n = 1219). Patients with high FIB-4 had significantly lower eGFR compared to those with low FIB-4 (85.37 ± 21.08 vs. 94.18 ± 20.17 mL/min/1.73 m2, p < 0.001). FIB-4 score was negatively correlated with eGFR (r = - 0.149, p < 0.001). In age-stratified multivariate analysis adjusted for diabetes mellitus, hypertension, BMI, sex, SGLT2 inhibitor use, and uric acid, FIB-4 score remained an independent predictor of reduced eGFR in both age groups (< 65 years: B = - 2.586, 95% CI [- 3.025, - 2.148], p < 0.001; ≥ 65 years: B = - 1.384, 95% CI [- 2.326, - 0.443], p = 0.004). eGFR decreased progressively across cardiometabolic risk score categories, from approximately 105 mL/min/1.73 m2 (score 1) to approximately 87 mL/min/1.73 m2 (score 5). KDIGO-based staging revealed a higher prevalence of advanced CKD stages in the high FIB-4 group (p < 0.001).
Conclusions
Hepatic fibrosis severity, as quantified by the FIB-4 index, is independently associated with impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors. These findings support the role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification. Clinicians should systematically monitor renal function in MASLD patients, particularly those with elevated FIB-4 scores.
Metabolic dysfunction-associated steatotic liver disease (MASLD) shares key pathophysiological mechanisms with cardiovascular disease. The Fibrosis-4 (FIB-4) score is a well-established tool for assessing liver fibrosis in MASLD. The FIB-4 score is known to be useful for predicting the risk of heart failure as we...
S. K. Ryu, S. Shin, C.-W. Goh· European Heart Journal· 0 citations
To identify factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) and to inform clinical risk stratification.
We retrospectively included adults hospitalized in the Department of Endocrinology,...
Yi Ding, Xue-Fei Ma, Ya-Fei Luo et al.· Frontiers in Endocrinology· 0 citations
Background
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disorder. Although cardiovascular disease is the leading cause of mortality in MASLD, the relationship between liver fibrosis severity and congestive heart failure (CHF) at the popul...
Shoubhit P. A. Nair, Tapesh Lalotra, Shreya Khankar et al.· Circulation· 0 citations
Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge, and cardiovascular mortality has been shown to be significantly associated with the cardiometabolic index (CMI). However, data linking CMI with histological severity in MASLD are lacking. In this stu...
Saima Fakih, Kaya Eda, A. Kırık et al.· Hepatology Forum· 0 citations
Liver disease is common in heart failure (HF) and is associated with worse outcomes, although the pathophysiological mechanisms remain poorly understood. Previous studies suggest that liver fibrosis without steatosis carries a poorer prognosis in HF patients.
We report the outcomes and clinical characteris...
M. Z. K. Tow, W. Ouwerkerk, M. Win et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.